Merck & Co Portfolio Analysis: Concentration in Healthcare and Significant New Position in Entrada Therapeutics (TRDA)
This analysis details Merck & Co's portfolio holdings as of June 30, 2026, highlighting its near-total concentration within the Healthcare sector and a notable increase in shares of Entrada Therapeutics.
As of June 30, 2026, Merck & Co., Inc. maintains a highly concentrated portfolio focused exclusively on the Healthcare sector. The total value of its holdings stands at $460,036,545.
The investor's largest position is in Personalis Inc (PSNL), valued at approximately $188.2 million and accounting for 35.75% of the portfolio. This represents a substantial allocation but shows no change from the previous period, as indicated by zero share movement data.
Moderna Inc (MRNA) follows closely with a stock value of $161.6 million and an allocation of 30.71%. Similarly, Kymera Therapeutics Inc (KYMR), valued at $88.5 million or about 16.82% of the portfolio, also demonstrates no change in shares held this quarter.
Turning to changes, Merck & Co's portfolio saw a single significant alteration during this period: an increase in its position in Entrada Therapeutics Inc (TRDA). The total stock value attributed to TRDA rose dramatically from $0.00 to $12.8 million, reflecting a 100% increase in shares held.
While the other three holdings - Viridian Therapeutics Inc (VRDN), Alecto Inc (ALEC), and another position at Personalis Inc (PSNL) - remained static with no change disclosed for their share counts or values, this new stake in TRDA significantly impacted the portfolio's structure.
It is important to note that there are no other disclosed changes. No large purchases beyond TRDA were reported, and no sales resulted in any exits from these positions during this quarter. The Healthcare sector allocation remains 100% of Merck & Co's total portfolio value.